Gilead Sciences, Inc.Foster City, California, United States
Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Private Company)
521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study
Saturday, October 19, 202412:20 PM – 12:25 PM US PT
